Wednesday, 14 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 9, 2026

When Will Bitcoin Bottom? Fidelity Macro Chief Says This Is The Metric To Watch

View original at finance.yahoo.com
When Will Bitcoin Bottom? Fidelity Macro Chief Says This Is The Metric To Watch Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bitcoin should be evaluated by the gold-to-Bitcoin ratio

    60% confidence
  • Gold is currently expensive relative to Bitcoin but not yet at levels seen during previous peaks

    60% confidence
  • Bitcoin will need to spend more time backing and potentially filling at the $60-$70k level, and perhaps even slightly undercut it, to satisfy both the time and price elements of a mild Bitcoin winter

    60% confidence
  • The military campaign could send Bitcoin higher, with longer duration increasing odds of Federal Reserve cutting interest rates

    60% confidence
  • This year would be a down year for Bitcoin, citing its historical four-year cycle and gold's outperformance

    60% confidence
  • Bitcoin should be evaluated by the gold-to-Bitcoin ratio

    60% confidence
  • Military campaign could send Bitcoin higher, with longer continuation increasing odds of Federal Reserve rate cuts

    60% confidence
  • Gold is currently expensive relative to Bitcoin but not yet at levels seen during previous peaks, which have historically marked inflection points for the digital asset

    60% confidence
  • Bitcoin will need to spend more time backing and potentially filling at the $60-$70k level, and perhaps even slightly undercut it, to satisfy both the time and price elements of a mild Bitcoin winter

    60% confidence
  • Bitcoin will need to spend more time backing and potentially filling at the $60-$70k level, and perhaps even slightly undercut it, to satisfy both the time and price elements of a mild Bitcoin winter

    60% confidence
  • Gold is currently expensive relative to Bitcoin but not yet at levels seen during previous peaks, which have historically marked inflection points for the digital asset

    60% confidence
  • This year would be a down year for Bitcoin, citing its historical four-year cycle and gold's outperformance

    60% confidence
  • The military campaign could send Bitcoin higher, claiming the longer it continues, the higher the odds of the Federal Reserve cutting interest rates

    60% confidence
  • This year would be a down year for Bitcoin, citing its historical four-year cycle and gold's outperformance

    60% confidence
  • Gold is currently expensive relative to Bitcoin but not yet at levels seen during previous peaks, which have historically marked inflection points for the digital asset

    60% confidence
  • Bitcoin should be evaluated by the gold-to-Bitcoin ratio, calling the digital asset a secondary play in the hard-money narrative, like silver

    60% confidence
  • Bitcoin is a secondary play in the hard-money narrative, like silver

    60% confidence
  • This year would be a down year for Bitcoin, citing its historical four-year cycle and gold's outperformance

    60% confidence
  • The military campaign could send Bitcoin higher, claiming the longer it continues, the higher the odds of the Federal Reserve cutting interest rates

    60% confidence
  • Bitcoin should be evaluated by the gold-to-Bitcoin ratio, calling the digital asset a secondary play in the hard-money narrative, like silver

    60% confidence
  • Bitcoin should be evaluated by the gold-to-Bitcoin ratio, calling the digital asset a secondary play in the hard-money narrative, like silver

    60% confidence
  • Bitcoin should be evaluated by the gold-to-Bitcoin ratio, calling the digital asset a secondary play in the hard-money narrative, like silver

    60% confidence
  • The military campaign could send Bitcoin higher, claiming the longer it continues, the higher the odds of the Federal Reserve cutting interest rates

    60% confidence
  • Gold is currently expensive relative to Bitcoin but not yet at levels seen during previous peaks

    60% confidence
  • Bitcoin is a secondary play in the hard-money narrative, like silver

    60% confidence
  • The military campaign could send Bitcoin higher, claiming the longer it continues, the higher the odds of the Federal Reserve cutting interest rates

    60% confidence
  • Bitcoin will need to spend more time backing and potentially filling at the $60-$70k level, and perhaps even slightly undercut it, to satisfy both the time and price elements of a mild Bitcoin winter

    60% confidence
  • Bitcoin will need to spend more time backing and potentially filling at the $60-$70k level, and perhaps even slightly undercut it, to satisfy both the time and price elements of a mild Bitcoin winter

    60% confidence
  • Gold is currently expensive relative to Bitcoin but not yet at levels seen during previous peaks, which have historically marked inflection points for the digital asset

    60% confidence
  • 2025 would be a down year for Bitcoin citing historical four-year cycle and gold's outperformance

    60% confidence

Data points we hold from this source

Elf Labs · market presence30 countries
Elf Labs · trademarks and copyrights500 count
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
When Will Bitcoin Bottom? Fidelity Macro Chief Says This Is The Metric To Watch — Source | Via News | ViaNews EU